BTAIQOTCPharmaceutical PreparationsFiscal year ends December 31

BioXcel Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$0.03−0.00 (-13.49%)

Close on Oct 19, 2026

Market cap: $757.50K
P/E (TTM): –
Dividend yield: –

BioXcel Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31
Revenue	0.64	2.27	1.38	0.38	–	–	–	–	–
Cost of Revenue	0.16	2.14	1.26	0.02	–	–	–	–	–
Gross Profit	0.48	0.12	0.12	0.36	–	–	–	–	–
Research & Development	30	30	84	91	53	58	26	15	2.69
Selling, General & Admin	20	34	83	69	54	–	–	–	–
General & Administrative	–	–	–	–	54	24	7.80	5.40	1.85
Operating Expenses	–	–	–	–	107	82	34	20	4.54
Total Costs & Expenses	51	70	173	160	107	–	–	–	–
Operating Income	-50	-67	-172	-160	-107	-82	-34	-20	-4.54
Interest Expense	17	15	13	8.21	0.04	0.03	0.02	–	–
Interest & Investment Income	1.07	2.60	5.65	2.53	0.04	0.16	–	–	–
Other Non-Operating Income	-3.52	20	0.39	-0.43	–	–	–	–	–
Merger & Restructuring Charges	0.19	2.44	4.16	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	0.00	-0.02	-0.05	–	–	–	–
Income Tax Expense	0	0	0	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	-70	-60	-179	-166	-107	-82	-33	-19	-4.54
Net Income	-70	-60	-179	-166	-107	-82	-33	-19	-4.54
EPS (Basic)(per share)	-5.73	-23.51	-98.33	-94.72	-64.80	-60.64	-32.32	-21.12	-7.52
EPS (Diluted)(per share)	-5.73	-23.51	-98.33	-94.72	-64.80	-60.64	-32.32	-21.12	-7.52
Shares Outstanding (Basic, Weighted)(shares)	12	2.54	1.82	1.75	1.65	1.36	1.02	0.91	0.61
Shares Outstanding (Diluted, Weighted)(shares)	12	2.54	1.82	1.75	1.65	1.36	1.02	0.91	0.61
EBITDA	–	–	–	–	-107	-82	-33	-20	-4.54

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 53.1%
Operating margin: -6054.7%
Net margin: -9549.9%
Return on equity, FY2025: 74.1%

Financial strength

Current ratio: 0.21
Debt to equity: -0.90
Debt to assets: 362.7%
Cash to current liabilities: 9.4%

Valuation

P/E ratio: –
Price to sales: 1.02
Price to book: –
Dividend yield: –